Integrative Medicine: Potential Applications in Dermatological and Endocrine Diseases - A Literature Review

August 2023 in “ Journal of Education, Health and Sport ”

Piotr MACHOWIEC, Marcela MAKSYMOWICZ, Anna KORZENIOWSKA, Natalia Baran, Adriana BIELAK, Andrea Nowak, Łucja CYWKA, Weronika SZWED, Andrea Nowak, Klaudia BOGUSZ

Traditional Chinese Medicine Chinese herbs chronic urticaria psoriasis benign thyroid nodules mitochondria β-cells diabetes mellitus TCM herbal medicine hives thyroid nodules diabetes

TLDR Combining conventional and Chinese herbal medicine could help treat some skin and hormone-related diseases.

The review paper discusses the potential use of Traditional Chinese Medicine (TCM), specifically Chinese herbs, in treating certain dermatological and endocrine diseases. The authors highlight that Chinese medicine has been effective in reducing chronic urticaria activity and psoriasis area severity index. It has also improved the response rate and reduced the maximum nodule diameter of benign thyroid nodules. Additionally, certain Chinese herbs have been reported to improve the functioning of mitochondria in β-cells, contributing to better management of patients with diabetes mellitus. The authors conclude that Chinese medicine could be a valuable supplement to conventional medicine in treating some chronic diseases and emphasize the need for further research and development of high efficacy, low toxicity pharmaceutical products conforming to international standards.

View this study on apcz.umk.pl →

Discuss this study in the Community →

Related Community Posts Join

6 / 141 results

community Surprisingly thorough study on He-Shou-Wu/Fo Ti

in Research/Science 14 upvotes 1 year ago

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

community Reddit’s amatorial meta analysis of 17 already avaliable hair loss prevention treatments that were found to be effective in clinical studies but are not FDA approved for MPB. PROS and CONS. (2022 Guide if Finasteride and Minoxidil are not working/ give you sides/are not enough) 77 studies linked!

in Research/Science 586 upvotes 2 years ago

The post and conversation are about hair loss treatments that have been found to be effective in studies. There are 19 different treatments mentioned, including oral minoxidil, oral dutasteride, topical finasteride, RU58841, and more. The best treatment for an individual depends on factors like availability, cost, side effects, and personal preferences.

community Is anyone using melatonin for hair loss?

in Research/Science 9 upvotes 6 months ago

Melatonin is being discussed as a potential treatment for hair loss, with questions about its effectiveness and whether it should be used topically or orally. No specific conclusions or personal experiences were shared.

community What should we lookout for in the near future for hairloss?

in Research/Science 17 upvotes 1 year ago

The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.

community 18->24 six years of Fin and Minox…. I guess we can’t all be winners 😭

in Progress Pictures 572 upvotes 2 years ago

A user named "EgyptStar81" who has been dealing with hair loss since age 15 due to genetics, chemotherapy and finasteride/minoxidil treatment. Possible solutions such as dutasteride, oral minoxidil, hair transplants and extensions were suggested.

community Binding affinity of pyrilutamide!

in Update 167 upvotes 2 years ago

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.